Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Triple Negative Breast Neoplasms 2Sarcoma 2Rhabdomyosarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Hodgkin Disease 2Burkitt Lymphoma 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Teratoma 1Sarcoma, Ewing 1Renal Pelvis and Ureter Urothelial Carcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pain 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms, Germ Cell and Embryonal 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1Leukemia 1Heart Failure 1Glioma 1Fallopian Tube Neoplasms 1Desmoplastic Small Round Cell Tumor 1Dendritic Cell Sarcoma, Interdigitating 1Choriocarcinoma 1Central Nervous System Neoplasms 1Cardiotoxicity 1

Interventions

Temozolomide 6Cyclophosphamide 5cabozantinib 4Vincristine 4fludarabine 3Radiotherapy 3Irinotecan 3liposomal doxorubicin 2irinotecan sucrosofate 2Zoledronic Acid 2Topotecan 2Specimen Handling 2PM 01183 2Ifosfamide 2Etoposide 2Eflornithine 2Drug Therapy 2Doxorubicin 2trilaciclib 1trifluridine tipiracil drug combination 1talazoparib 1silmitasertib 1romiplostim 1regorafenib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1naxitamab 1fluzoparib 1fludarabine phosphate 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Sarcoma, Ewing × pegfilgrastim × Clear all
NCT06709495 2026-02-19

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
63 enrolled
Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡